{"product_id":"acrs-five-forces","title":"(ACRS) Aclaris Therapeutics, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aclaris Therapeutics, Inc. Porter's Five Forces Analysis shows the competitive pressures shaping the company’s market position, including rivalry, buyer and supplier power, substitutes, and new entrants. The page already includes a real preview of the report content, so you can see the style before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API and reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. relies on niche API, assay materials, and biologic reagents that are not easy to swap. In clinical-stage development, even one failed lot or delayed shipment can push timelines by weeks or months, so key suppliers can press for higher prices or stricter terms. This supplier power is high because Aclaris has limited ability to commoditize these inputs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. depends on CDMOs for formulation, scale-up, and clinical supply work, so it has little direct control over capacity or timing. Qualified GMP manufacturers are limited, and tight biologics and sterile supply capacity keeps switching costs high and pricing firm. That dependence gives suppliers strong bargaining power over Aclaris Therapeutics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. depends on clinical research sites, CROs, central labs, and data vendors to run trials, and these partners control work that is hard to replace. Because their methods are specialized and tightly regulated, switching them can slow programs and add cost. That keeps supplier power moderate to high, especially when timelines are tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScarce scientific talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. faces high supplier power from scarce scientific talent: experienced immunology, translational, and clinical operations staff are limited, so biotech employers bid against each other for the same people. That can push pay up and delay programs; in 2025, life-science hiring stayed tight, making human capital a supplier input, not just a cost line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScarce talent raises wage pressure.\u003c\/li\u003e\n\u003cli\u003eOpen roles can slow trials.\u003c\/li\u003e\n\u003cli\u003eHuman capital acts like a supplier.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and licensing inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. may need outside patents, assay tech, and deal rights to push programs forward, so IP holders can set the price. In 2025\/2026 biotech licensing deals, upfront cash, milestones, and low-double-digit royalties are common when science is differentiated, which lifts supplier power.\u003c\/p\u003e\n\u003cp\u003eFor Aclaris Therapeutics, Inc., that matters because each key licensed tool can gate trial speed and program scope. If the underlying IP is validated, licensors can demand richer terms, tighter field limits, or more control over sublicensing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed IP can delay or raise program cost\u003c\/li\u003e\n\u003cli\u003eValidated science supports higher royalty asks\u003c\/li\u003e\n\u003cli\u003eMilestones and field limits cut Aclaris flexibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAclaris Faces High Supplier Power, Costs, and Delay Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. faces high supplier power because GMP CDMOs, CROs, central labs, and niche API and reagent vendors are hard to replace, and one delay can push a program back by weeks or months. In 2025\/2026, scarce biotech talent also kept wage pressure high, while licensed IP often carried upfront cash, milestones, and low-double-digit royalties. That makes supplier terms a real cost and timeline risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier input\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003cth\u003e2025\/2026 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs and GMP sites\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eLimited capacity, high switching cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific talent\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePay pressure, slower hiring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed IP\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eUpfront cash, milestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored analysis of Aclaris Therapeutics, Inc.’s competitive forces, highlighting supplier power, buyer influence, new entrants, substitutes, and industry rivalry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAclaris Therapeutics’ Five Forces snapshot quickly reveals competitive pressure, helping you make faster, sharper strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Aclaris Therapeutics, Inc. that helps verify assumptions fast and supports sharper investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed products yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. has no marketed products, so it does not face normal end-customer bargaining yet. With no product sales, customer power is effectively nil; near-term value is driven by regulators, trial data, and partners, not buyers. In FY2025, that meant zero commercial pricing pressure and no retail demand to negotiate against.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and formulary control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf Aclaris Therapeutics, Inc. reaches the market, insurers, pharmacy benefit managers, and health systems will shape access through prior authorization, step edits, and formulary tiers. In the US, the top 3 PBMs control about 80% of prescription claims, so reimbursement can outweigh strong immunology data and push buyer power very high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician prescribing choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermatologists, rheumatologists, and gastroenterologists can choose from many approved and off-label options, so prescribers still control uptake. Aclaris Therapeutics, Inc. has no material product revenue in its latest filings, which shows adoption depends on physician confidence, not patient pull. Before switching, doctors weigh efficacy, safety, convenience, and real-world data, so bargaining power stays meaningful.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner negotiation leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Aclaris Therapeutics, Inc., customer bargaining power is high because future licensing or co-development partners can push for better economics, especially when they can choose among multiple small biotech deals. Large pharma buyers also have scale and in-house R\u0026amp;D, so they can wait, compare assets, and press for lower upfronts or heavier milestones. Unless Aclaris shows strong clinical proof, that leverage can cut deal value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh partner power for small biotech\u003c\/li\u003e\n\u003cli\u003eBig pharma has many alternatives\u003c\/li\u003e\n\u003cli\u003eClear data can protect pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient expectations give customers real leverage: in chronic inflammatory diseases, many patients want fast relief, simple dosing, and a strong safety profile, and they often drop therapies that cause side effects or need frequent monitoring. Across chronic disease care, about 50% of patients do not stay on long-term therapy, so even small tolerability issues can cut adoption and share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast relief drives switching\u003c\/li\u003e\n\u003cli\u003eSafety can outweigh efficacy\u003c\/li\u003e\n\u003cli\u003eConvenience supports retention\u003c\/li\u003e\n\u003cli\u003ePoor tolerability raises churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAclaris Has High Customer Power Risk Despite Zero FY2025 Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power is high for Aclaris Therapeutics, Inc. in FY2025 because it has no marketed products and zero product revenue, so there is no direct buyer pricing pressure yet.\u003c\/p\u003e\n\u003cp\u003eIf assets launch, PBMs, insurers, and prescribers can still push back; the top 3 PBMs handle about 80% of US prescription claims.\u003c\/p\u003e\n\u003cp\u003eIn chronic care, about 50% of patients do not stay on long-term therapy, so safety, convenience, and speed of relief can drive switching.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBM claim share\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term therapy nonadherence\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAclaris Therapeutics, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Aclaris Therapeutics, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no mockups, no placeholders. The document is fully formatted and ready to use, so what you’re viewing now is the same file you’ll download instantly after payment. Buy with confidence knowing there are no surprises—just the complete analysis, exactly as displayed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded immunology field\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. faces intense rivalry in immunology because many biotech and large pharma firms target the same diseases, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and IBD. The field has dozens of active clinical programs, so pipeline crowding is high and differentiation is hard. This keeps pricing power and market share gains under pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple mechanism competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. faces broad competitive rivalry because its pipeline can be challenged by JAK inhibitors, biologics, TYK2 agents, and other targeted immune therapies in the same disease areas. Competitors do not need the same mechanism to win; they can use different science, trial designs, and dosing to target the same indications. That widens the rivalry set far beyond direct peers and raises pressure on speed, efficacy, and safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBig pharma scale advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBig pharma’s scale is a real edge: Pfizer posted $58.5 billion in 2024 revenue and spent $10.7 billion on R\u0026amp;D, while Aclaris is still a clinical-stage player. That gap lets larger firms fund longer trials, absorb failures, and keep multiple programs moving at once. For Aclaris Therapeutics, Inc., this means more pressure on pricing, trial speed, and deal power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRace for differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is intense because Aclaris Therapeutics, Inc. must prove better efficacy, safety, or dosing convenience than current standards. In 2024, Aclaris Therapeutics, Inc. reported $4.0 million in revenue and a $111.2 million net loss, so even small clinical wins can matter for partner interest and adoption. One weak efficacy signal can end a program fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall clinical gaps can decide partner deals.\u003c\/li\u003e\n\u003cli\u003eSafety and dosing can beat pure efficacy.\u003c\/li\u003e\n\u003cli\u003eWeak differentiation raises launch risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline and deal competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePipeline and deal rivalry is intense because Aclaris Therapeutics, Inc. competes for patients, capital, trial sites, investigators, and licensing rights at the same time. In biotech, investors can back hundreds of stories, so a small pipeline must fight hard for attention and partner interest. That keeps pricing power low and raises the cost of standing out.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAclaris Therapeutics, Inc. faces capital scarcity.\u003c\/li\u003e\n\u003cli\u003eTrial sites and investigators are contested.\u003c\/li\u003e\n\u003cli\u003eLicensing talks are crowded and selective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAclaris Faces Fierce Competition in Crowded Immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because Aclaris Therapeutics, Inc. competes in crowded immunology areas where many biotech and large pharma firms chase the same patients. Bigger rivals can fund more programs, move faster, and absorb failures better. That keeps pricing power low and raises the bar for Aclaris Therapeutics, Inc. to win on efficacy, safety, or dosing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAclaris Therapeutics, Inc.\u003c\/th\u003e\n\u003cth\u003ePfizer\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$4.0M\u003c\/td\u003e\n\u003ctd\u003e$58.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net loss\u003c\/td\u003e\n\u003ctd\u003e$111.2M\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eclinical-stage\u003c\/td\u003e\n\u003ctd\u003e$10.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved therapies already exist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Aclaris Therapeutics, Inc.'s target dermatology markets, patients already have approved biologics and oral small molecules, including Dupixent, Adbry, Ebglyss, Rinvoq, and Cibinqo. These are immediate standards of care, so any new Aclaris candidate must beat proven efficacy, safety, and convenience to win share. That makes the threat of substitutes high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric and off patent options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder immunosuppressants and supportive therapies can still replace newer branded drugs when doctors want a familiar, lower-cost option. In the U.S., generics fill about 90% of prescriptions but account for roughly 15% of drug spending, so cost-sensitive buyers often move down-market fast. That keeps substitute pressure high for Aclaris Therapeutics, Inc., especially where efficacy gaps are small.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferent mechanisms of action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEven if Aclaris Therapeutics, Inc. wins approval, doctors can still pick other drug classes that work through different pathways. In dermatology, patients already have many options, including JAK inhibitors, corticosteroids, calcineurin inhibitors, and biologics, so no single family has control; the FDA has approved 10+ JAK or biologic therapies across key skin and immune uses. That keeps substitution pressure high and pricing power limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNonpharmacologic care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNonpharmacologic care is a modest substitute for Aclaris Therapeutics, Inc. in inflammatory skin disease: US eczema affects about 31.6 million people, and many start with diet changes, topical care, or trigger control before drug therapy. These steps can delay or trim prescription use, but they rarely replace advanced treatment in moderate-to-severe cases.\u003c\/p\u003e\n\u003cp\u003eIn practice, this keeps substitution pressure real but limited. Procedures, symptom care, and lifestyle shifts can lower near-term demand for specialty drugs, yet they usually work best as add-ons, not full replacements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDelays drug start.\u003c\/li\u003e\n\u003cli\u003eLowers mild-case demand.\u003c\/li\u003e\n\u003cli\u003eRarely replaces advanced therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging next-gen drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmerging next-gen drugs keep substitution risk high for Aclaris Therapeutics, Inc. because the biotech pipeline keeps adding better-selective, safer options; the U.S. FDA approved 55 novel drugs in 2024, showing how fast new entrants reach market. Even after launch, Aclaris Therapeutics, Inc. candidates can lose share if a newer therapy proves cleaner or easier to use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e55 FDA novel drugs approved in 2024\u003c\/li\u003e\n\u003cli\u003eNew launches can displace Aclaris Therapeutics, Inc.\u003c\/li\u003e\n\u003cli\u003eInnovation keeps substitution pressure persistent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitute Pressure Weighs on Aclaris’s Dermatology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Aclaris Therapeutics, Inc. is high: approved biologics, oral small molecules, and older immunosuppressants already cover the same dermatology use cases, so new drugs must beat proven efficacy, safety, and convenience. Low-cost generics and non-drug care also cap pricing power, while fresh pipeline launches can quickly displace weak candidates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eAbout 90% of US prescriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovel FDA drugs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e55 approved in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEczema self-care\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003e31.6 million US cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug development is a long, costly gate: preclinical work, multi-phase trials, and FDA review often take 10+ years and can cost about $2.3 billion per approved drug. In immunology and oncology, trial failure rates stay high, so casual entrants face heavy cash burn and long delays before any revenue. That keeps Aclaris Therapeutics, Inc.'s threat of new entrants low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensive development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapital intensity keeps Aclaris Therapeutics, Inc. safe from new biotech rivals: drug discovery, clinical trials, and GMP manufacturing can burn through hundreds of millions before a product reaches market. In 2025, Aclaris still had to fund research-heavy losses and long trial timelines, which shows how much cash a new entrant must raise just to stay alive. Many programs fail before approval, so underfunded startups usually run out of money before they can compete.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed for scientific expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuccessful entry needs deep immunology, medicinal chemistry, clinical development, and safety expertise. Drug R\u0026amp;D still takes about 10-15 years and can cost over $1 billion per approved therapy, so weak teams burn cash fast. The talent pool is small and highly competed for, which makes scale hard for new firms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and platform barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAclaris Therapeutics, Inc. faces moderate new-entrant risk because patents, trade secrets, and platform know-how can block direct copycats. In biologics and immunology, entrants often must license protected tech or spend years building around it, which raises cost and delay. FDA drug development still often takes about 8-12 years, so IP-backed barriers matter.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, Aclaris Therapeutics, Inc. still relies on proprietary programs and platform assets, so a rival must clear legal, scientific, and capital hurdles before matching its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents slow direct imitation\u003c\/li\u003e\n\u003cli\u003eLicensing adds cost and delay\u003c\/li\u003e\n\u003cli\u003ePlatform know-how is hard to copy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBut biotech formation remains active\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech entry is still active: academic spinouts and venture-backed startups keep launching with novel mechanisms, even with high R\u0026amp;D and regulatory barriers. Outsourcing to CROs and CDMOs cuts upfront capex, so a new team can start with a small headcount and outsourced labs. For Aclaris Therapeutics, Inc., that makes the threat of new entrants moderate, not low.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNovel science still attracts capital\u003c\/li\u003e\n\u003cli\u003eCRO\/CDMO outsourcing lowers startup cost\u003c\/li\u003e\n\u003cli\u003eBarriers slow entrants, but do not block them\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAclaris: Moderate Entry Barriers, But No Easy Copycats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Aclaris Therapeutics, Inc. stays moderate: FDA paths still take about 10-15 years, and approved drugs often cost about $2.3 billion to develop. Outsourced CRO and CDMO models let venture-backed startups launch lean, so barriers slow rivals but do not block them. Patents and platform know-how still protect Aclaris Therapeutics, Inc. from easy copycats.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost\u003c\/td\u003e\n\u003ctd\u003eAbout $2.3B per drug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTimeline\u003c\/td\u003e\n\u003ctd\u003e10-15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntry mode\u003c\/td\u003e\n\u003ctd\u003eCRO\/CDMO lowers capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234049532169,"sku":"acrs-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/acrs-five-forces.webp?v=1785709343","url":"https:\/\/dcfanalyst.com\/products\/acrs-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}